253595-72-1 Usage
Uses
Used in Pharmaceutical Industry:
Z-N-ME-THR-OH CHA is used as a building block in peptide synthesis for the development of new drugs and therapeutic agents. The modification of threonine with a methyl group can enhance the stability, solubility, and bioavailability of the peptide, leading to improved pharmacological properties.
Used in Biochemical Research:
Z-N-ME-THR-OH CHA is used as a research tool to study protein structure and function. The methylated threonine residue can be incorporated into peptides and proteins to investigate the effects of post-translational modifications on protein folding, stability, and interactions with other biomolecules.
Used in Drug Design:
Z-N-ME-THR-OH CHA is used in the design of novel drugs and therapeutic agents. The modification of threonine with a methyl group can alter the biological activity of the peptide, providing a means to optimize the potency, selectivity, and pharmacokinetic properties of drug candidates.
Used in Peptide Synthesis:
Z-N-ME-THR-OH CHA is used as a protected amino acid in the synthesis of peptides and peptide-based drugs. The N-terminal protecting group (Z) ensures that the threonine residue is selectively incorporated into the peptide chain, allowing for the controlled assembly of complex peptide structures.
Check Digit Verification of cas no
The CAS Registry Mumber 253595-72-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,3,5,9 and 5 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 253595-72:
(8*2)+(7*5)+(6*3)+(5*5)+(4*9)+(3*5)+(2*7)+(1*2)=161
161 % 10 = 1
So 253595-72-1 is a valid CAS Registry Number.
253595-72-1Relevant academic research and scientific papers
NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME
-
Paragraph 3779-3781; 4855-4856, (2015/10/05)
The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.
Determination of the complete absolute configuration of petriellin A
Aurelio, Luigi,Brownlee, Robert T. C.,Dang, Jason,Hughes, Andrew B.,Polya, Gideon M.
, p. 407 - 414 (2008/02/04)
We report the full structural determination of the depsipeptide petriellin A. The absolute configuration of the amino acid residues, N-methyl isoleucine and N-methyl threonine, have been determined by a combination of HPLC and TLC comparison of synthetic Marfey's derivatives and Marfey's derivatives of the natural product hydrolysate. The configuration of the chiral centres in these two N-methylated residues was found to be the same as those of the common unmethylated l-amino acids. CSIRO 2006.
